Why Organogenesis Holdings Stock Is Soaring Today

What happened?

Shares of Organogenesis Holdings (NASDAQ: ORGO) are up by 15.5% as of 1:15 p.m. EDT on Thursday after rising by as much as 28% earlier today. The drugmaker is enjoying nice gains on the stock market following its release of preliminary financial results for the third quarter.

So what

For the third quarter ending on Sept. 30, Organogenesis Holdings expects its revenue to come in between $99 million and $100 million. This would represent an increase of 54% to 56% compared to the third quarter of the previous fiscal year. Organogenesis Holdings' top line is also set to exceed the $71.96 million average estimate analysts were expecting. The company also expects to record positive adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) and a positive generally accepted accounting principles (GAAP) net income for the third quarter.

Dollar bills stacked in a growing bar graph pattern.

Image source: Getty Images.

Last year, Organogenesis Holdings recorded a net loss per share of $0.12. Analysts also expected red ink on Organogenesis Holdings' bottom line for the third quarter to the tune of a net loss per share of $0.08. Further, Organogenesis Holdings revised its guidance for the full fiscal year. The company previously expected its revenue to be between $273 million and $277 million. Now, Organogenesis Holdings expects revenue in the range of $311 million and $314 million. Lastly, Organogenesis Holdings will report a GAAP net income this year after failing to do so last year.

Now what

Organogenesis Holdings will report its full financial results after the market closes on Nov. 9. Given today's sneak peek, investors can expect some great things when the healthcare company does so.

10 stocks we like better than Organogenesis Holdings Inc
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Organogenesis Holdings Inc wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of September 24, 2020

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More